Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases

Background The variability in the association of host innate immune response to Hepatitis C virus (HCV) infection requires ruling out the possible role of host KIR and HLA genotypes in HCV-related disorders: therefore, we therefore explored the relationships between KIR/HLA genotypes and chronic HCV infection (CHC) as they relate to the risk of HCV-related hepatocarcinoma (HCC) or lymphoproliferative disease progression. Methods and Findings We analyzed data from 396 HCV-positive patients with CHC (n = 125), HCC (118), and lymphoproliferative diseases (153), and 501 HCV-negative patients. All were HIV and HBV negative. KIR-SSO was used to determine the KIR typing. KIR2DL5 and KIR2DS4 variants were performed using PCR and GeneScan analysis. HLA/class-I genotyping was performed using PCR-sequence-based typing. The interaction between the KIR gene and ligand HLA molecules was investigated. Differences in frequencies were estimated using Fisher’s exact test, and Cochran-Armitage trend test. The non-random association of KIR alleles was estimated using the linkage disequilibrium test. We found an association of KIR2DS2/KIR2DL2 genes, with the HCV-related lymphoproliferative disorders. Furthermore, individuals with a HLA-Bw6 KIR3DL1+ combination of genes showed higher risk of developing lymphoma than cryoglobulinemia. KIR2DS3 gene was found to be the principal gene associated with chronic HCV infection, while a reduction of HLA-Bw4 + KIR3DS1+ was associated with an increased risk of developing HCC. Conclusions Our data highlight a role of the innate-system in developing HCV-related disorders and specifically KIR2DS3 and KIR2D genes demonstrated an ability to direct HCV disease progression, and mainly towards lymphoproliferative disorders. Moreover the determination of KIR3D/HLA combination of genes direct the HCV progression towards a lymphoma rather than an hepatic disease. In this contest IFN-α therapy, a standard therapy for HCV-infection and lymphoproliferative diseases, known to be able to transiently enhance the cytotoxicity of NK-cells support the role of NK cells to counterstain HCV-related and lymphoproliferative diseases.

[1]  F. Izzo,et al.  Correction: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases , 2015, PloS one.

[2]  Tony Tse,et al.  The proposed rule for U.S. clinical trial registration and results submission. , 2015, The New England journal of medicine.

[3]  A. Gabrielli,et al.  Validation of the classification criteria for cryoglobulinaemic vasculitis. , 2014, Rheumatology.

[4]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[5]  Zhong-jin,et al.  Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection. , 2014 .

[6]  R. Talamini,et al.  Erratum: Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy (PLoS ONE (2014) 9:1 (e84940) doi:10.1371/journal.pone.0084940) , 2014 .

[7]  F. Izzo,et al.  Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection , 2014, BioMed research international.

[8]  R. Talamini,et al.  Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy , 2014, PloS one.

[9]  C. Carcassi,et al.  Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma. , 2013, Human immunology.

[10]  C. Cho,et al.  Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy , 2013, British Journal of Cancer.

[11]  G. Missale,et al.  HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus–Related Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[12]  A. Minguela,et al.  KIR Gene Mismatching and KIR/C Ligands in Liver Transplantation: Consequences for Short-Term Liver Allograft Injury , 2013, Transplantation.

[13]  M. Makuuchi,et al.  Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Parham,et al.  Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3 , 2012, Front. Immun..

[15]  T. Greten,et al.  Cellular Immune Suppressor Mechanisms in Patients with Hepatocellular Carcinoma , 2012, Digestive Diseases.

[16]  A. Folgori,et al.  Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. , 2012, Gastroenterology.

[17]  M. Binder,et al.  Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. , 2012, FEMS microbiology reviews.

[18]  M. Manns,et al.  Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. , 2012, The Journal of infectious diseases.

[19]  S. Kent,et al.  HIV Infection Abrogates the Functional Advantage of Natural Killer Cells Educated through KIR3DL1/HLA-Bw4 Interactions To Mediate Anti-HIV Antibody-Dependent Cellular Cytotoxicity , 2012, Journal of Virology.

[20]  G. Tan,et al.  The Therapeutic Effect of Cytokine-Induced Killer Cells on Pancreatic Cancer Enhanced by Dendritic Cells Pulsed with K-Ras Mutant Peptide , 2011, Clinical & developmental immunology.

[21]  L. Butterfield,et al.  Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients , 2011, Clinical & developmental immunology.

[22]  V. Canzonieri,et al.  KIR/HLA Combination Associated with the Risk of Complications in Celiac Disease , 2011, The International journal of biological markers.

[23]  M. Altfeld,et al.  Common HIV-1 Peptide Variants Mediate Differential Binding of KIR3DL1 to HLA-Bw4 Molecules , 2011, Journal of Virology.

[24]  C. O’Farrelly,et al.  Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection , 2011, Proceedings of the National Academy of Sciences.

[25]  J. Fischer,et al.  Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. , 2011, Blood.

[26]  H. Atkins,et al.  Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors , 2010, PloS one.

[27]  Peter Parham,et al.  Different Patterns of Evolution in the Centromeric and Telomeric Regions of Group A and B Haplotypes of the Human Killer Cell Ig-Like Receptor Locus , 2010, PloS one.

[28]  Andrew R. Jones,et al.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..

[29]  Chien-Jen Chen,et al.  Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Cambon-Thomsen,et al.  Linkage disequilibrium organization of the human KIR superlocus: implications for KIR data analyses , 2010, Immunogenetics.

[31]  S. Khakoo,et al.  Natural killer cells and hepatitis C: action and reaction , 2010, Gut.

[32]  Hans-Gustaf Ljunggren,et al.  Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. , 2010, Gastroenterology.

[33]  G. Alexander,et al.  Consistent beneficial effects of killer cell immunoglobulin‐like receptor 2DL3 and group 1 human leukocyte antigen‐C following exposure to hepatitis C virus , 2010, Hepatology.

[34]  M. Libra,et al.  HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. , 2010, Tissue antigens.

[35]  M. Brazzoli,et al.  Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. , 2010, Journal of hepatology.

[36]  S. Rowland-Jones,et al.  Dimorphic Motifs in D0 and D1+D2 Domains of Killer Cell Ig-Like Receptor 3DL1 Combine to Form Receptors with High, Moderate, and No Avidity for the Complex of a Peptide Derived from HIV and HLA-A*24021 , 2009, The Journal of Immunology.

[37]  B. Gao,et al.  Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases , 2009, Journal of leukocyte biology.

[38]  Z. Husain,et al.  Protective KIR-HLA interactions for HCV infection in intravenous drug users. , 2009, Molecular immunology.

[39]  M. Cardillo,et al.  Killer cell immunoglobulin‐like receptor genotype and killer cell immunoglobulin‐like receptor–human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[40]  P. Tien,et al.  Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. , 2008, Clinical immunology.

[41]  Yoshinobu Sato,et al.  Sustained response to interferon‐α plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[42]  D. Sansonno,et al.  Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development. , 2008, Blood.

[43]  M. Carrington,et al.  Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. , 2008, The Journal of clinical investigation.

[44]  Yoshiyuki Suzuki,et al.  Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. , 2007, The American journal of medicine.

[45]  N. Hayashi,et al.  Intrahepatic delivery of α‐galactosylceramide‐pulsed dendritic cells suppresses liver tumor , 2007 .

[46]  J. Glass,et al.  Cytokine-activated natural killer cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[47]  L. Rodrigo,et al.  Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. , 2005, Journal of Infectious Diseases.

[48]  J. Orange,et al.  Natural killer cells inhibit hepatitis C virus expression , 2004, Journal of leukocyte biology.

[49]  N. Hayashi,et al.  Concanavalin a injection activates intrahepatic innate immune cells to provoke an antitumor effect in murine liver , 2004, Hepatology.

[50]  Salim I. Khakoo,et al.  HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection , 2004, Science.

[51]  F. Christiansen,et al.  Comparative genomic analysis, diversity and evolution of two KIR haplotypes A and B. , 2004, Gene.

[52]  N. Hayashi,et al.  CD1d‐mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver , 2003, International journal of cancer.

[53]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[54]  J. Orange.  Human natural killer cell deficiencies and susceptibility to infection. , 2002, Microbes and infection.

[55]  Peter Parham,et al.  Some human KIR haplotypes contain two KIR2DL5 genes: KIR2DL5A and KIR2DL5B , 2002, Immunogenetics.

[56]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[57]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[58]  Eric O Long,et al.  Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. , 1998, Journal of immunology.

[59]  J. Niu,et al.  Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[60]  N. Hayashi,et al.  Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor. , 2007, Hepatology.

[61]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .